• Publications
  • Influence
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer and severe or life-threatening diarrhea was more frequent in the irinotican-plus-cisplatin group than in the etoposide-plus -cis Platin group.
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
  • T. Takano, Y. Ohe, T. Tamura
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 1 October 2005
EGFR mutations and increased copy numbers were significantly associated with better clinical outcome in gefitinib-treated NSCLC patients.
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology
This study strongly suggests that cisplatin plus etoposide and concurrent radiotherapy is more effective for the treatment of LS-SCLC than cisPlatin plus Etoposid and sequential radiotherapy.
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Gefitinib significantly improved objective response rate and quality of life versus docetaxel; progression-free survival, disease control rates, and symptom improvement were similar for the two treatments.
Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer
It is suggested that patients with EGFR mutations seem to have better outcomes with gefitinib treatment, in terms of progression-free survival, overall survival, and response, than those patients without EG FR mutations.
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape. Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
The addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone in patients with advanced squamous NSCLC and the safety profile was consistent with that observed in previous lung and melanoma studies.